NCT02260141

Brief Summary

To study the effectiveness of d-ribose in treating Alzheimer's and Dementia

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
3

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Sep 2014

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2014

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

October 5, 2014

Completed
4 days until next milestone

First Posted

Study publicly available on registry

October 9, 2014

Completed
3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2017

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2017

Completed
Last Updated

May 8, 2020

Status Verified

October 1, 2017

Enrollment Period

3.1 years

First QC Date

October 5, 2014

Last Update Submit

May 6, 2020

Conditions

AlzheimersDementia

Outcome Measures

Primary Outcomes (1)

  • ADAS-ADL

    2 months

Study Arms (1)

Treatment with d-ribose

EXPERIMENTAL

Treatment with ribose 5 gm TID

Dietary Supplement: d-ribose

Interventions

d-riboseDIETARY_SUPPLEMENT

giving ribose in those with a diagnosis of Alzheimer's and/or dementia

Treatment with d-ribose

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • A diagnosis of Alzheimer's and/or dementia with a Mini Mental Status Exam ( MMSE) score over 12 or being ambulatory and able to travel outside the home with assistance.
  • Must have a caregiver living with them.

You may not qualify if:

  • Overt and severe causes of secondary dementia such as metastatic brain cancers, or severe overt infectious encephalopathies or severe autoimmune illness.
  • Also, severe life threatening illnesses which would make them unlikely to be alive after 6-12 months.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

PAN

Kailua, Hawaii, 96740, United States

Location

MeSH Terms

Conditions

Dementia

Interventions

Ribose

Condition Hierarchy (Ancestors)

Brain DiseasesCentral Nervous System DiseasesNervous System DiseasesNeurocognitive DisordersMental Disorders

Intervention Hierarchy (Ancestors)

PentosesMonosaccharidesSugarsCarbohydrates

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Model Details: Single arm pilot study using ribose for alzheimers
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 5, 2014

First Posted

October 9, 2014

Study Start

September 1, 2014

Primary Completion

October 1, 2017

Study Completion

October 1, 2017

Last Updated

May 8, 2020

Record last verified: 2017-10

Data Sharing

IPD Sharing
Will not share

Locations

US(1)